Belite Bio (NASDAQ:BLTE) is a small company with multiple phase 3 trials targeting retinal degenerative eye diseases. The stock looks interesting, with late-stage trials...
Investing.com — Down one day and up the next: oil’s interim volatility isn’t letting up, with bullish Chinese data propping up crude prices Thursday,...